Mirae Asset Global Investments Co., Ltd. Atea Pharmaceuticals, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

$28 Billion
Q2 2025

A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 3,306 shares of AVIR stock, worth $11,339. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,306

Previous 2,826 16.99%

Holding current value

$11,339

Previous $8,000 37.5%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 21, 2025	BUY	$2.55 - $3.6 $1,224 - $1,728	480 Added 16.99%	3,306 $11,000
Q1 2025 Apr 24, 2025	BUY	$2.9 - $3.52 $31 - $38	11 Added 0.39%	2,826 $8,000
Q4 2024 Jan 27, 2025	SELL	$2.93 - $3.82 $697 - $909	-238 Reduced 7.8%	2,815 $9,000
Q3 2024 Oct 23, 2024	BUY	$3.17 - $4.02 $1,705 - $2,162	538 Added 21.39%	3,053 $10,000
Q2 2024 Jul 30, 2024	SELL	$3.31 - $4.04 $92,514 - $112,918	-27,950 Reduced 91.74%	2,515 $8,000
Q1 2024 May 01, 2024	BUY	$3.09 - $4.56 $94,136 - $138,920	30,465 New	30,465 $123,000
Q3 2023 Oct 26, 2023	BUY	$3.0 - $3.79 $219 - $276	73 Added 0.24%	29,926 $89,000
Q2 2023 Aug 10, 2023	SELL	$3.21 - $5.06 $545 - $860	-170 Reduced 0.57%	29,853 $111,000
Q1 2023 May 04, 2023	SELL	$3.0 - $4.97 $156 - $258	-52 Reduced 0.17%	30,023 $100,000
Q4 2022 Feb 09, 2023	BUY	$4.35 - $6.17 $130 - $185	30 Added 0.1%	30,075 $144,000
Q3 2022 Nov 10, 2022	BUY	$5.49 - $8.79 $52,945 - $84,770	9,644 Added 47.27%	30,045 $171,000
Q2 2022 Jul 26, 2022	BUY	$5.33 - $8.18 $108,737 - $166,880	20,401 New	20,401 $145,000

Others Institutions Holding AVIR

# of Institutions

109

Shares Held

48.3M

Call Options Held

3.4K

Put Options Held

14.5K

View Full List

About Atea Pharmaceuticals, Inc.

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $286M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

More about AVIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Account

Mirae Asset Global Investments Co., Ltd. Atea Pharmaceuticals, Inc. Transaction History